A patient with schizophrenia shows suicidal behaviors, and the provider orders clozapine (Clozaril). The nurse teaches the family about the medication and its side effects. Lab results reveal: RBC 4.7 million/mcL, WBC 2000/mcL, and TSH 1.3 mc-IU. Which statement by a family member indicates a need for further teaching about this drug?

Clozapine is an atypical antipsychotic reserved for treatment-resistant schizophrenia and for patients with persistent suicidal behavior. It is highly effective but carries a serious risk of agranulocytosis, requiring strict hematologic monitoring. Regular assessment of white blood cell (WBC) count and absolute neutrophil count (ANC) is essential to detect bone marrow suppression early. Patient and family education focuses on monitoring schedules and recognizing signs of infection.

Rationale:
A. An ANC below 1000/mcL (moderate neutropenia) requires the medication to be interrupted, but it does not mandate permanentdiscontinuation. Usually, the drug is held and the patient is monitored daily. Once the ANC rises above 1000/mcL, the patient can often be "rechallenged" or restarted on the drug with increased monitoring. Permanent discontinuation is typically only required for "generalized agranulocytosis" (ANC < 500/mcL) or if a patient fails a rechallenge.

B. Blood counts must continue to be monitored for several weeks after discontinuation because neutropenia or agranulocytosis can persist or develop even after the medication is stopped. Ongoing surveillance ensures early detection of delayed complications. This reflects accurate understanding of post-discontinuation care.

C. Weekly blood work is required during the initial phase of clozapine therapy to closely monitor for early signs of neutropenia. Although frequency may later decrease, early intensive monitoring is essential for safety. This statement demonstrates appropriate knowledge of the monitoring protocol.

D. Fever, sore throat, and oral ulcers are key early signs of infection related to neutropenia. Immediate reporting is critical because reduced neutrophil levels impair the body’s ability to fight infections. Recognizing these symptoms supports timely intervention and reflects correct understanding.

Chronic management of mania in Bipolar disorder focuses on long-term mood stabilization to prevent recurrent manic and depressive episodes. Maintenance therapy aims to reduce relapse risk, stabilize mood fluctuations, and improve overall functioning. Mood stabilizers are the cornerstone of treatment, with certain agents having strong evidence for both acute and long-term control. Selection depends on effectiveness, safety profile, and patient-specific factors.

Rationale:
A. Valproic acid is an effective mood stabilizer used in both acute mania and maintenance therapy, particularly in patients with rapid cycling or mixed episodes. However, while widely used, it is generally considered an alternative to lithium rather than the primary first-line agent for chronic management.

B. Sufentanil is a potent opioid used for anesthesia and severe pain management, not for psychiatric conditions. It has no role in mood stabilization or the treatment of bipolar disorder. Its pharmacologic effects are related to analgesia and sedation, making it inappropriate.

C. Lithium is the gold-standard medication for long-term management of bipolar disorder. It effectively reduces the frequency and severity of manic and depressive episodes and has proven anti-suicidal benefits. Its mechanism involves modulation of neurotransmitter systems and intracellular signaling pathways, making it highly effective for chronic stabilization.

D. Imipramine is a tricyclic antidepressant used to treat depression but is not appropriate for bipolar disorder maintenance. Antidepressants alone can precipitate manic episodes in bipolar patients if not combined with a mood stabilizer. Its use does not address the underlying mood instability of mania.